An Integrated Model of Care for Inflammatory Bowel Disease Sufferers in Australia: Development and the Effects of Its Implementation
Overview
Affiliations
Background: Psychological comorbidities are associated with poor outcome and increased healthcare utilization in patients with inflammatory bowel disease (IBD). However, a model of care addressing the biopsychosocial dimension of disease is not routinely applied in IBD. This review describes the development of such a model and the effects of its implementation in a hospital-based cohort of patients with IBD.
Methods: Three different approaches were used: 1) collecting baseline epidemiological data on mental health comorbidities; 2) raising awareness of and targeting mental health problems; 3) examining the effects of the model implementation.
Results: High rates of anxiety and depressive symptoms (36% and 13%, respectively) that are maintained over time were identified in IBD patients presenting at a metropolitan teaching hospital. Patients with documented psychological comorbidities were more likely to be hospitalized than those without (odds ratio [OR] = 4.13, 95% confidence interval [CI]: 1.25, 13.61). Improvements in disease activity, anxiety, depression, quality of life, and coping have been noted when cognitive-behavioral therapy (CBT) was provided to patients. A drop in the use of opiates (P = 0.037) and hospitalization rates (from 48% to 30%) in IBD patients has been noted as a result of introduction of the changed model of care. In addition, the mean total cost of inpatient care was lower for IBD patients than controls (US$12,857.48 [US$15,236.79] vs. US$ 30,467.78 [US$ 53,760.20], P = 0.005).
Conclusion: Our data to date suggest that an integrated model of care for patients with IBD may yield superior long-term outcomes in terms of medication use and hospitalization rates and reduce healthcare costs.
Treat to target in Crohn's disease: A practical guide for clinicians.
Srinivasan A World J Gastroenterol. 2024; 30(1):50-69.
PMID: 38293329 PMC: 10823901. DOI: 10.3748/wjg.v30.i1.50.
Norouzkhani N, Bahari A, Shirvani J, Faramarzi M, Eslami S, Tabesh H Front Psychol. 2023; 14:1224279.
PMID: 37809295 PMC: 10557489. DOI: 10.3389/fpsyg.2023.1224279.
Sacks O, Goldwag J, Eid M, Shaw R, Williams T, Ivatury S Crohns Colitis 360. 2023; 3(1):otaa096.
PMID: 36777068 PMC: 9802267. DOI: 10.1093/crocol/otaa096.
Agrawal M, Spencer E, Colombel J, Ungaro R Gastroenterology. 2021; 161(1):47-65.
PMID: 33940007 PMC: 8640961. DOI: 10.1053/j.gastro.2021.04.063.
New Zealand National Audit of Outpatient Inflammatory Bowel Disease Standards of Care.
Hackett R, Gearry R, Ho C, McCombie A, Mackay M, Murdoch K Clin Exp Gastroenterol. 2020; 13:285-292.
PMID: 32884323 PMC: 7434564. DOI: 10.2147/CEG.S259790.